We are incredibly proud to share that Kartos Therapeutics has entered into a definitive agreement to be acquired by Ipsen. This acquisition represents a significant step forward for our lead asset, navtemadlin (oral MDM2 inhibitor), and our mission to transform care for patients with myelofibrosis #MPNSM ipsen.com/press-release/ipse…

Meet POIESIS: A global mission to optimize #Myelofibrosis care with navtemadlin (MDM2 inhibitor). ✅ Phase 3 ✅ Actively enrolling ✅ Innovative & practical design. Let's improve myelofibrosis outcomes. We can do it! #MPNSM 📄👇 doi.org/10.1080/14796694.202…

This #RareDiseaseDay, we stand with people living with myelofibrosis and the families, caregivers, and advocates beside them. At Kartos Therapeutics, we recognize the daily challenges of this rare blood cancer and remain committed to advancing awareness, supporting research, and working toward better outcomes and quality of life for every patient. No one should feel overlooked because their condition is rare. Together, we’re driving progress, compassion, and hope. #Myelofibrosis #RareDiseaseDay2026 #ShowYourStripes

We recently spoke with @pankitvachhani of @UABNews, who discussed the potential of MDM2 inhibitors for treating MPNs, outlining the encouraging results observed to date with the MDM2 inhibitor navtemadlin. Click here to watch: 🎥 ow.ly/xWAZ50X4UcV #MPNsm #HemOnc

@Kartosthera is proud to support patients and families whose journeys inspire resilience and hope. Together, through awareness and research, we can create a brighter future. #MPNsm #MakeSenseOfMPN

@Kartosthera is excited to announce that we'll be attending the #SOHO2025 Congress! If you're planning to be there, we'd love to connect. See you in Houston! #MPNsm

We spoke with @bose_prithviraj of @MDAndersonNews at the #MPNWorkshop25 to hear about the potential of the MDM2 inhibitor navtemadlin in #myelofibrosis, and to learn about the unique design of the POIESIS trial.🩸 Watch here: 👉 ow.ly/NAMU50WMCwK 👈 #CTSM #MPNsm #HemOnc

This #BloodCancerAwarenessMonth, Kartos Therapeutics is proud to stand with patients, caregivers and healthcare professionals as we advance research and innovation to improve lives. #buildhopeMPN #MPNsm

Kartos is excited to share the US launch of a website to support our global Ph3 study #POIESISTrial of navtemadlin (MDM2i) or placebo as add-on to ruxolitinib in patients with myelofibrosis who have a suboptimal response to ruxolitinib treatment. Future website launches in other participating countries to follow soon. This study is now enrolling! Find out more at poiesis-trial.com/ #MPNSM #MPNs

Published by @VJHemOnc vjhemonc.com/video/kad5gc0yo…

Published by @VJHemOnc vjhemonc.com/video/e5cmmvufr…

Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis @IcahnMountSinai @MountSinaiNYC @ASH_hematology #ASH24 #hematology onclive.com/view/navtemadlin…

CONGRESS | #ASH24 | PRESENTATION John Mascarenhas @IcahnMountSinai shares findings from the phase III BOREAS study investigating navtemadlin vs BAT in JAK inhibitor R/R MF (N = 183). Navtemadlin monotherapy was safe and effective, demonstrating clinically relevant efficacy with disease-modifying potential. The rate of SVR35 and TSS50 at Week 24 was three-fold and two-fold higher with navtemadlin vs BAT, validating the novel approach of MDM2 inhibition in pts with MF. Follow our live feed for more updates: mpn-hub.com/medical-informat…… #MPN #MPNsm #MedicalCongress

The MDM2 inhibitor navtemadlin may target cancer-driving cells and alter its progression in patients with relapsed or refractory myelofibrosis, according to data from a phase 3 trial presented at #ASH24. #MPNs #BloodCancer Read here: curetoday.com/view/navtemadl…

Navtemadlin reduced disease biomarkers in relapsed/refractory myelofibrosis, suggesting it targets disease-driving cells and alters progression. Data from the phase 3 BOREAS trial were presented at #ASH24. #mpnsm | @IcahnMountSinai @ASH_hematology targetedonc.com/view/navtema…

#ASH24 Compared with best available therapies, treatment with the MDM2 inhibitor #navtemadlin led to greater improvements in SVR35 and TSS50 among patients with #myelofibrosis that was R/R to JAK inhibitors: ow.ly/3KXt50Un7OT

Disease-driving cells in patients with relapsed/refractory myelofibrosis may be targetable with the investigational p53-potentiating, best-in-class MDM2 inhibitor navtemadlin. #ASH24 | @ASH_hematology cancernetwork.com/view/novel…

Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis @ASH_hematology #ASH24 #mpnsm #oncology onclive.com/view/navtemadlin…

#ASH24 Booth 2147. #MPNSM #DiscoveriesBeyondTheOrdinary

DO NOT BE AFRAID. Beneath the surface lies a future reimagined. Explore novel innovations in myelofibrosis at #ThePortal at #ASH24, Booth 2147. #MPNSM #DiscoveriesBeyondTheOrdinary